Decentralized Cell Processing for Clinical Trials: A Sponsor’s Guide

When a clinical trial requires apheresis-derived starting material from patients enrolled at sites across multiple states, the supply chain question becomes unavoidable: where does the blood go, and what happens to it after collection?

The centralized model has been the default answer for most cell therapy programs. Blood is drawn at an enrolled clinical site, the leukapheresis product ships overnight to a central processing laboratory, processing begins 18-24 hours after collection, and finished material returns to wherever it is needed in the trial. For some programs, this works without issue. For programs where material quality is tightly correlated with time from collection to processing, the overnight shipment step introduces variability that compounds through the manufacturing process.

Decentralized cell processing offers a different architecture: move processing infrastructure close to the collection site, reduce the window between apheresis completion and the first processing step, and eliminate overnight shipping from the starting material supply chain. The material quality picture changes. So does the logistics complexity, though in different ways.

This guide covers what decentralized processing means operationally, when it outperforms the centralized model, what the regulatory framework requires under 21 CFR 1271, how to evaluate whether a supplier’s decentralized infrastructure is operational or aspirational, and how OrganaBio’s Cell Processing Center network was built to address these specific supply chain variables.

The Centralized Model’s Supply Chain Problem

Centralized cell processing optimizes for economies of scale. A single high-throughput facility can invest in validated equipment, experienced operators, and quality systems in ways that are difficult to replicate across multiple smaller sites. For programs using healthy allogeneic donor material, where the donor population is broadly normal and the manufacturing process is well-characterized, centralized processing makes economic and operational sense.

The problem is not the centralized model itself. The problem is what happens to leukapheresis product during overnight shipping.

Fresh leukapheresis product is time-sensitive in ways that a single post-thaw viability number does not fully capture. Monocyte contamination increases with time at room temperature. CD4/CD8 ratios shift as different cell populations respond differently to environmental stress. Granulocytes degranulate, releasing enzymes that alter the cellular environment for co-isolated cells. These changes accumulate along a gradient. The product is not fine at hour 4 and failed at hour 5, but quality does degrade continuously from the moment of collection.

Published research has documented what this looks like at the extremes: PBMC samples that scored above 90% viability on standard assays had completely lost the ability to respond to mitogenic stimulation. High viability score, zero functional capacity. For healthy donor material in research settings, 18-24 hours at proper temperature may not cross this threshold. For patient-derived material in autologous CAR-T programs, where the donor’s immune system is already under pressure from disease and prior treatment, the same time window carries different risk.

There are documented quality thresholds that predict manufacturing failure in CAR-T programs: monocyte contamination above 40% CD14+ blocks transduction. Starting material CD4:CD8 ratios below 1:3 are associated with manufacturing failure in published hematology research. One large study found a 25% manufacturing failure rate for lymphoma patients in which starting material variables were identified as root cause.

The centralized model cannot change the physics of overnight shipping. Decentralized processing can change how much time elapses between collection and the first centrifuge spin.

What Decentralized Cell Processing Means Operationally

Decentralized cell processing is not a synonym for multiple collection sites. A program can have apheresis collections happening at a dozen sites across the country while running a fully centralized processing model: collections happen locally, but all processing happens at one central facility.

True decentralization means processing capacity is distributed across the collection network. The key operational question is not where the apheresis machine is located. It is where the centrifuge is, and how much time passes between the apheresis suite and the first density gradient separation step.

In a fully decentralized model:

• Apheresis collection happens at or near a Cell Processing Center
• Leukapheresis product moves directly from the collection suite to the processing laboratory, with no overnight shipment and no cold chain logistics across state lines
• The window from collection completion to first centrifuge spin is measured in minutes to a few hours
• Finished material ships to the manufacturing facility or trial site

In the centralized model, fresh leukapheresis product ships overnight, processing begins the next day, and the overnight shipment window is an unavoidable part of the supply chain. In the decentralized model, that window is eliminated for sites within the processing network’s reach.

This does not mean decentralized processing is always superior. It means it addresses a specific supply chain variable, handling time from collection to processing, that matters most in specific program contexts.

When Decentralized Processing Makes Sense for Your Trial

Decentralized processing is not the right model for every cell therapy program. The case for it is strongest when several conditions are present simultaneously.

Autologous Starting Material Programs

Autologous CAR-T, TCR therapy, and other programs using patient-derived material are the primary clinical context where the collection-to-processing window has documented downstream consequences. Patient donors cannot be screened or selected the way healthy allogeneic donors can. You work with the immune status the patient presents with, compromised by disease, by prior chemotherapy, by whatever treatment history precedes the apheresis. The CMC team’s levers for managing starting material quality are limited, and reducing processing delay is one of the most impactful ones available.

Multi-Site Enrollment With Dispersed Geography

A single-center trial can run centralized processing without meaningful supply chain risk. The logistics calculus changes as enrollment geography widens. A Phase II trial enrolling at 15 sites across the country has 15 potential overnight shipment windows, and not all of them will perform identically. Shipment delays, temperature excursions, and chain-of-identity documentation issues do not distribute evenly across sites.

Decentralized processing with regional Cell Processing Centers eliminates the overnight shipment step for sites that fall within the CPC network’s catchment. The question becomes not “how do we manage overnight shipping from 15 sites” but “which sites are within the CPC network and which need a different logistics solution.”

Programs Approaching Phase II Scale

Phase I trials often enroll at a single site or a small cluster of sites, where centralized processing is logistically manageable. As programs advance and the enrollment footprint expands, the operational complexity of centralized processing scales accordingly. Supply chain infrastructure decisions made at Phase I can become constraints at Phase II if they were not designed for expansion.

Evaluating decentralized processing as a potential Phase II supply chain model before the Phase II expansion happens, rather than after, gives sponsors more flexibility in site selection and enrollment geography.

Programs Enrolling in Markets Underserved by Existing Infrastructure

The commercial apheresis and centralized processing network is concentrated in major academic medical centers and population centers. Clinical trials enrolling at community hospitals, regional oncology practices, or smaller academic centers in mid-sized markets may be logistically constrained by the centralized model in ways that decentralized regional infrastructure addresses.

Regional CPC networks that expand into underserved markets do not just improve logistics for existing trial designs. They make enrollment possible at sites that would otherwise be excluded because overnight shipping logistics were too complex or the material quality risk was too high.

Regulatory Framework: 21 CFR 1271 and Decentralized Processing

Human cell, tissue, and cellular and tissue-based products processed for clinical use fall under 21 CFR 1271, which establishes Good Tissue Practice requirements. This regulatory framework applies to leukapheresis processing facilities whether they are centralized or decentralized.

The regulatory question for decentralized processing is not whether 21 CFR 1271 applies. It applies to each processing location. The question is how the distributed model is structured to meet GTP requirements consistently across all sites.

Facility Registration

Under 21 CFR 1271, HCT/P establishments that process tissue for clinical use must register with FDA. Each physical processing location in a decentralized network requires its own registration, not just the central organizational entity. When evaluating a supplier’s decentralized network, FDA establishment registration verification is the first compliance due diligence step. A supplier claiming to operate a network of processing locations with a single FDA registration is either operating under a specific regulatory arrangement that should be documented and explained, or has not completed registration requirements for all network locations.

Harmonized SOPs and Quality Management Systems

GTP requires documented standard operating procedures covering all processing steps from receipt of apheresis product through final release. In a decentralized model, these SOPs must be harmonized across all locations, with the same procedures, acceptance criteria, documentation standards, and quality systems at each CPC, enforced by a central quality oversight function with authority over all network locations.

A decentralized network where each location has independently developed its own procedures may be individually compliant at each site while producing material that is not comparably characterized across locations. For sponsors running multi-site trials where material processed at different network sites will be used in the same manufacturing runs, SOP harmonization is a material quality issue, not just a regulatory one.

Donor Eligibility and Chain-of-Identity Documentation

For autologous material, donor eligibility determination follows the IND protocol rather than standard allogeneic screening. Each processing facility in the network still needs documented procedures for handling autologous donor eligibility documentation, applied consistently across locations. Chain-of-identity documentation must follow the material through each handoff in the decentralized supply chain, with documentation requirements that meet both the GTP standard and any IND-specific requirements.

GTP Versus cGMP

21 CFR 1271 GTP and pharmaceutical cGMP under 21 CFR 211 are distinct regulatory frameworks with different documentation, validation, and oversight requirements. Early-phase IND sponsors working with leukapheresis starting material typically operate under GTP. Programs approaching Phase III and commercial manufacturing may require cGMP-compliant processing for some or all steps in the supply chain.

A supplier network that can clearly articulate which regulatory standard applies to which processing step, and that has the quality infrastructure to operate under both frameworks as programs advance, gives sponsors more flexibility in planning the transition from early-phase to late-phase manufacturing without a supplier change at a critical juncture.

Compliance Due Diligence Checklist

When evaluating a decentralized supplier for your IND, the compliance due diligence checklist should include:

• FDA HCT/P establishment registration numbers for each physical processing location
• The SOP library that governs all network locations and documentation of how cross-site harmonization is maintained
• The organizational structure of the quality function: is there a central quality authority with oversight of all network locations, or are quality decisions made locally at each site?
• How adverse reactions and product complaints are tracked and reported across network locations
• Documentation of any FDA interactions specific to the network’s decentralized structure

OrganaBio’s Cell Processing Center Model

OrganaBio’s Cell Processing Center network was built to operationalize the decentralized processing model for cell therapy programs that need distributed starting material supply chain infrastructure.

The first CPC was established in San Diego, serving the Southern California research and clinical trial corridor. The second, in Chicago, serves the Midwest and extends the network’s reach into a major clinical trial enrollment corridor that was previously only accessible through overnight shipping. The 6-city expansion roadmap extends this network into additional markets where clinical trial enrollment is concentrated and where current processing infrastructure coverage leaves gaps.

OrganaBio’s 30-minute standard is the time from receipt at the CPC to the first centrifuge spin. This is not a total processing time claim. It is the receipt-to-first-spin window, which is the period when the leukapheresis product is most vulnerable to the handling-related quality changes that compound through downstream processing steps.

The quality system that governs the CPC network uses harmonized SOPs and acceptance criteria across all locations. Processing performed in Chicago operates under the same documented procedures, the same release testing standards, and the same quality oversight as processing in San Diego. For sponsors, this comparability means that material from two different network locations in the same multi-site trial can be treated as equivalent for manufacturing purposes, a comparability claim that depends entirely on quality system harmonization being real rather than aspirational.

With the 2026 integration of Excellos Labs, OrganaBio’s CTDMO capability now spans apheresis coordination through the CPC network, processing and cryopreservation, and downstream manufacturing steps under a single quality system. The supply chain from collection through early-stage manufacturing can happen within one organizational structure, eliminating the supplier handoff between starting material provider and downstream manufacturer that represents one of the documented risk points in cell therapy CMC.

Decision Framework: Centralized vs. Decentralized

The right processing model depends on your program’s specific parameters. This framework maps the key decision variables.

Centralized processing is a strong fit when: your trial is enrolling at a single site or a small cluster of geographically proximate sites; you are using healthy allogeneic donor material where overnight shipping time is within acceptable limits for your application; your CMC team has an established, validated relationship with a central processing facility and the program is performing to specification; or the program is early Phase I with enrollment geography not yet determined.

Decentralized processing is a strong fit when: you are using autologous patient-derived material with documented quality-sensitive manufacturing; your trial is enrolling at geographically dispersed sites across multiple regions; one or more enrollment sites are in markets that are logistically difficult to serve from a single central facility; you are approaching Phase II scale and the enrollment geography is expanding; you want a single-source CTDMO with quality system coverage from collection through early manufacturing; or material turnaround time is on the clinical critical path and the overnight shipping window creates scheduling constraints in your patient conditioning and manufacturing workflow.

The Hybrid Approach

Some programs run a hybrid model: decentralized processing for enrollment sites within the CPC network, centralized processing for outlier sites where decentralized logistics are not yet viable. This is a reasonable approach for Phase II programs whose enrollment footprint extends beyond any current CPC network’s reach. The hybrid model works best when the quality systems at both the CPC locations and the central facility use comparable SOPs and acceptance criteria, so that material from different processing pathways can be characterized and compared.

Evaluating Supplier Network Readiness

A supplier describing decentralized processing capability and a supplier operating a compliant, functional, multi-site CPC network are different things. The due diligence questions that distinguish them:

FDA registration verification. Request the FDA HCT/P establishment registration number for each physical processing location. Verify independently through FDA’s public database. Registration for the corporate entity is not equivalent to registration for each processing facility.

SOP harmonization documentation. Request the SOP index that covers all network locations. Ask how cross-site consistency is verified and audited, and by whom. A network where each location has independently developed procedures is not operationally equivalent to a network with a harmonized quality system.

Cell quality data by location. Documented post-processing quality data from each location gives you a basis for comparing performance between network sites. Average viability, CD4/CD8 ratio maintenance, monocyte contamination profiles, granulocyte content: these metrics should be available by location, not just as a network aggregate.

Logistics and chain-of-identity documentation. Ask how collection appointments are scheduled across network sites. How is chain-of-identity documented from apheresis suite to processing suite? What happens when a collection is rescheduled or when incoming product fails QC? The answers reveal whether the logistics infrastructure is operational or theoretical.

Quality oversight structure. Who makes release decisions for processed material? Is there a central quality authority with oversight of all locations, or do individual sites make local release decisions? For multi-site trials where material from different CPC locations will be used interchangeably, centralized quality authority is not optional.

Working With OrganaBio’s CTDMO Team

If you are evaluating starting material supply chain options for a multi-site clinical trial, or if you are approaching Phase II scale and planning for what your supply chain looks like at 20 enrollment sites instead of 4, OrganaBio’s CTDMO team works with program teams on supply chain architecture questions before the IND is submitted.

The CPC network covers San Diego and Chicago, with the 6-city expansion underway. The quality system is harmonized across locations. The 30-minute receipt-to-processing window is the operational standard.

To discuss what the decentralized model looks like for your specific program, including site logistics, regulatory documentation requirements, and how the CPC network integrates with your trial design, contact OrganaBio’s CTDMO team.

Frequently Asked Questions